Heiko Kroth

This inventor holds 9 USPTO granted patents and 6 published patent applications, plus 2 CIPO patents and 4 EPO patents. Top assignees: Ac Immune Sa, Life Molecular Imaging Sa, Life Molecular Imaging Limited. Active years: 2014-2025.

USPTO Granted Patents = 9 (Patent Applications = 6)

% Patents Active = 77.8

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 4 (Patent Applications = 13)

Average Co-Inventor Count = 5.9

ph-index = 2

Forward Citations = 19(Granted Patents)

Company Filing History:

Life Molecular Imaging Sa

patents

1 out of 1

Life Molecular Imaging Limited

patent

where one patent can have more than one assignee

Years Active: 2014-2025

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12202840 - Compounds for the treatment or alleviation of disorders associated with Tau aggregates (2025-01-21),

2. 11306089 - Gamma-carboline compounds for the detection of Tau aggregates (2022-04-19),

3. 10865207 - Compounds for imaging Tau protein aggregates (2020-12-15),

4. 10835624 - Compounds for imaging Tau protein aggregates (2020-11-17),

5. 10662193 - Carbazole and carboline compounds for use in the diagnosis, treatment, alleviation or prevention of disorders associated with amyloid or amyloid-like proteins (2020-05-26),

6. 10500207 - Compounds for the treatment of diseases associated with amyloid or amyloid-like proteins (2019-12-10),

7. 9701660 - 2,6-diaminopyridine compounds suitable for treating diseases associated with amyloid or amyloid-like proteins or for treating or preventing ocular diseases or conditions associated with a pathological abnormality/change in the tissue of the visual system (2017-07-11),

8. 9221812 - Compounds for the treatment of diseases associated with amyloid or amyloid-like proteins (2015-12-29),

9. 8916590 - 2,6-diaminopyridine compounds suitable for treating diseases associated with amyloid or amyloid-like proteins or for treating or preventing ocular diseases or conditions associated with a pathological abnormality/change in the tissue of the visual system (2014-12-23),

Title: Heiko Kroth: Innovator in Tau Aggregate Research

Introduction

Heiko Kroth is a prominent inventor based in Ecublens, Switzerland. He has made significant contributions to the field of medical research, particularly in the treatment of disorders associated with Tau aggregates. With a total of nine patents to his name, Kroth's work is at the forefront of addressing critical health issues.

Latest Patents

Kroth's latest patents include innovative compounds aimed at treating or alleviating disorders related to Tau protein aggregates. One notable patent focuses on compounds for the treatment of disorders associated with Tau aggregates, including Alzheimer's disease. This invention presents novel compounds that can be employed in the treatment, alleviation, or prevention of conditions linked to Neurofibrillary Tangles (NFTs). Another significant patent involves gamma-carboline compounds designed for the selective detection of Tau aggregates. This invention utilizes Positron Emission Tomography (PET) imaging to identify disorders associated with Tau aggregates, such as Alzheimer's disease and other tauopathies.

Career Highlights

Throughout his career, Heiko Kroth has worked with notable companies in the medical field, including Ac Immune SA and Life Molecular Imaging SA. His expertise and innovative approach have positioned him as a key figure in the development of therapeutic solutions for neurodegenerative diseases.

Collaborations

Kroth has collaborated with esteemed colleagues, including Wolfgang Froestl and Andreas Muhs. These partnerships have further enhanced his research and contributed to the advancement of knowledge in the field of Tau-related disorders.

Conclusion

Heiko Kroth's contributions to the understanding and treatment of Tau aggregates are invaluable. His innovative patents and collaborations reflect his commitment to improving health outcomes for individuals affected by neurodegenerative diseases.